Acute kidney injury (AKI) constitutes a significant public health concern, with limited therapeutic options to mitigate injury or expedite recovery. A novel therapeutic approach, local renal treatment, encompassing pharmacotherapy and surgical interventions, has exhibited positive outcomes in AKI management. Peri-renal administration, employing various delivery routes, such as the renal artery, intrarenal, and subcapsular sites, has demonstrated superiority over peripheral intravenous infusion. This review evaluates different drug delivery methods, analyzing their benefits and limitations, and proposes potential improvements. Renal decapsulation, particularly with the availability of minimally invasive techniques, emerges as an effective procedure warranting renewed consideration for AKI treatment. The potential synergistic effects of combined drug delivery and renal decapsulation could further advance AKI therapies. Clinical studies have already begun to leverage the benefits of local renal treatments, and with ongoing technological advancements, these modalities are expected to increasingly outperform systemic intravenous therapy.
LameireNH, BaggaA, CruzD, et al.Acute kidney injury: An increasing global concern. Lancet, 2013; 382(9887):170–179.
3.
MehtaRL, CerdáJ, BurdmannEA, et al.International Society of Nephrology's 0by25 initiative for acute kidney injury (zero preventable deaths by 2025): A human rights case for nephrology. Lancet, 2015; 385(9987):2616–2643.
4.
SeeEJ, JayasingheK, GlassfordN, et al.Long-term risk of adverse outcomes after acute kidney injury: A systematic review and meta-analysis of cohort studies using consensus definitions of exposure. Kidney Int, 2019; 95(1):160–172.
5.
SatoY, TakahashiM, YanagitaM. Pathophysiology of AKI to CKD progression. Semin Nephrol, 2020; 40(2):206–215.
6.
ChawlaLS, EggersPW, StarRA, et al.Acute kidney injury and chronic kidney disease as interconnected syndromes. N Engl J Med, 2014; 371(1):58–66.
7.
FuZ, ZhangY, GengX, et al.Optimization strategies of mesenchymal stem cell-based therapy for acute kidney injury. Stem Cell Res Ther, 2023; 14(1):116.
8.
ChatterjeeUS. Renal capsulectomy for revival of renal function. J Pediatr Surg, 2023; 58(4):784–785.
9.
DrägerDL, ProtzelC, HakenbergOW. [Renal decapsulation for the treatment of anuria: A “forgotten” treatment from the early 20th century]. Urologe A, 2017; 56(1):54–59.
10.
StoneHH, FulenwiderJT. Renal decapsulation in the prevention of post-ischemic oliguria. Ann Surg, 1977; 186(3):343–355.
11.
MoriartyKP, LipkowitzGS, GermainMJ. Capsulectomy: A cure for the page kidney. J Pediatr Surg, 1997; 32(6):831–833.
12.
HerrlerT, TischerA, MeyerA, et al.The intrinsic renal compartment syndrome: New perspectives in kidney transplantation. Transplantation, 2010; 89(1):40–46.
13.
CrucesP, LilloP, SalasC, et al.Renal decapsulation prevents intrinsic renal compartment syndrome in ischemia-reperfusion-induced acute kidney injury: A physiologic approach. Crit Care Med, 2018; 46(2):216–222.
14.
OchiA, MuroS, AdachiT, et al.Zoning inside the renal fascia: The anatomical relationship between the urinary system and perirenal fat. Int J Urol, 2020; 27(7):625–633.
15.
WangH.Nephrology, 4th edition (in Chinese). People's Health Publishing House: Beijing; 2020; pp. 40–42.
16.
JuangJH, PengSJ, KuoCH, et al.Three-dimensional islet graft histology: Panoramic imaging of neural plasticity in sympathetic reinnervation of transplanted islets under the kidney capsule. Am J Physiol Endocrinol Metab, 2014; 306(5):E559–E570.
17.
SmoodB, BottinoR, HaraH, et al.Is the renal subcapsular space the preferred site for clinical porcine islet xenotransplantation? Review article. Int J Surg, 2019; 69:100–107.
18.
TodorovaD, KimJ, HamzeinejadS, et al.Brief report: Immune microenvironment determines the immunogenicity of induced pluripotent stem cell derivatives. Stem Cells, 2016; 34(2):510–515.
19.
LiuBX, SunW, KongXQ. Perirenal fat: A unique fat pad and potential target for cardiovascular disease. Angiology, 2019; 70(7):584–593.
20.
HerbertLA, ChenWC, HartmannA, et al.Mechanical properties of the dog renal capsule. J Appl Physiol, 1976; 40(2):164–170.
RaptopoulosV, KleinmanPK, MarksSJr, et al. Renal fascial pathway: Posterior extension of pancreatic effusions within the anterior pararenal space. Radiology, 1986; 158(2):367–374.
23.
MolmentiEP, BalfeDM, KantermanRY, et al.Anatomy of the retroperitoneum: Observations of the distribution of pathologic fluid collections. Radiology, 1996; 200(1):95–103.
24.
HakamN, LuiJL, ShawNM, et al.Cushioning the blow: Role of perirenal fat in renal trauma injury severity. BJU Int, 2023; 131(2):208–212.
25.
BoydEM, LowerAH. Neutral fat of the perirenal fat depots. Can J Biochem Physiol, 1957; 35(2):157–160.
26.
LeverJD, JungRT, NnodimJO, et al.Demonstration of a catecholaminergic innervation in human perirenal brown adipose tissue at various ages in the adult. Anat Rec, 1986; 215(3):251–255, 27–29.
27.
HausmanGJ. Anatomical and enzyme histochemical differentiation of adipose tissue. Int J Obes, 1985; 9 (Suppl 1):1–6.
28.
KimJH, HanEH, JinZW, et al.Fetal topographical anatomy of the upper abdominal lymphatics: Its specific features in comparison with other abdominopelvic regions. Anat Rec (Hoboken), 2012; 295(1):91–104.
29.
CzajaK, KraelingR, KlimczukM, et al.Distribution of ganglionic sympathetic neurons supplying the subcutaneous, perirenal and mesentery fat tissue depots in the pig. Acta Neurobiol Exp (Wars), 2002; 62(4):227–234.
30.
MeyersMA, FriedenbergRM, KingMC, et al.The significance of the renal capsular arteries. Br J Radiol, 1967; 40(480):949–956.
31.
HolmesMJ, O'MorchoePJ, O'MorchoeCC. Morphology of the intrarenal lymphatic system. Capsular and hilar communications. Am J Anat, 1977; 149(3):333–351.
32.
AdlerJT. Gray's anatomy: The anatomical basis of clinical practice. J Surg Res, 2010; 158(1):28–29.
33.
ZhouXJ, LaszikZG, NadasdyT, et al.Silva's Diagnostic Renal Pathology. Cambridge University Press: Cambridge, United Kingdom; 2017.
34.
CoffmanTM, SchrierRW. Schrier's Diseases of the Kidney (9th ed.). Wolters Kluwer Health/Lippincott Williams & Wilkins: Philadelphia; 2013.
LiP, LiuB, WuX, et al.Perirenal adipose afferent nerves sustain pathological high blood pressure in rats. Nat Commun, 2022; 13(1):3130.
37.
WuW, ZhengHG, ZhangDW, et al.[Study on the biological characteristics of adipose stem cells derived from renal adipose capsule cultured in vitro]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, 2010; 26(11):1078–1081.
38.
ParkHC, YasudaK, KuoMC, et al.Renal capsule as a stem cell niche. Am J Physiol Renal Physiol, 2010; 298(5):F1254–F1262.
39.
ChesbroughRM, BurkhardTK, MartinezAJ, et al.Gerota versus Zuckerkandl: The renal fascia revisited. Radiology, 1989; 173(3):845–846.
40.
MarxWJ, PatelSK. Renal fascia: Its radiographic importance. Urology, 1979; 13(1):1–7.
SchrepferS, DeuseT, ReichenspurnerH, et al.Stem cell transplantation: The lung barrier. Transplant Proc, 2007; 39(2):573–576.
43.
SanteramoI, Herrera PerezZ, IlleraA, et al.Human kidney-derived cells ameliorate acute kidney injury without engrafting into renal tissue. Stem Cells Transl Med, 2017; 6(5):1373–1384.
44.
LeibacherJ, HenschlerR. Biodistribution, migration and homing of systemically applied mesenchymal stem/stromal cells. Stem Cell Res Ther, 2016; 7:7.
45.
EggenhoferE, BenselerV, KroemerA, et al.Mesenchymal stem cells are short-lived and do not migrate beyond the lungs after intravenous infusion. Front Immunol, 2012; 3:297.
46.
FischerUM, HartingMT, JimenezF, et al.Pulmonary passage is a major obstacle for intravenous stem cell delivery: The pulmonary first-pass effect. Stem Cells Dev, 2009; 18(5):683–692.
47.
Sanchez-DiazM, Quiñones-VicoMI, Sanabria de la TorreR, et al.Biodistribution of mesenchymal stromal cells after administration in animal models and humans: A systematic review. J Clin Med, 2021;10(13).
48.
UllahM, LiuDD, RaiS, et al.A novel approach to deliver therapeutic extracellular vesicles directly into the mouse kidney via its arterial blood supply. Cells, 2020;9(4).
49.
LeeMS, LeeFY, ChenYL, et al.Investigated the safety of intra-renal arterial transfusion of autologous CD34+ cells and time courses of creatinine levels, endothelial dysfunction biomarkers and micro-RNAs in chronic kidney disease patients—phase I clinical trial. Oncotarget, 2017; 8(11):17750–17762.
50.
YangCC, SungPH, ChengBC, et al.Safety and efficacy of intrarenal arterial autologous CD34+ cell transfusion in patients with chronic kidney disease: A randomized, open-label, controlled phase II clinical trial. Stem Cells Transl Med, 2020; 9(8):827–838.
51.
MunkA, DuvaldCS, PedersenM, et al.Dosing limitation for intra-renal arterial infusion of mesenchymal stromal cells. Int J Mol Sci, 2022;23(15).
52.
StenvinkelP, WadströmJ, BertramT, et al.Implantation of autologous selected renal cells in diabetic chronic kidney disease stages 3 and 4—clinical experience of a “first in human” study. Kidney Int Rep, 2016; 1(3):105–113.
53.
ShultzLD, GoodwinN, IshikawaF, et al.Subcapsular transplantation of tissue in the kidney. Cold Spring Harb Protoc, 2014; 2014(7):737–740.
54.
Kazazi-HyseniF, ZandstraJ, PopaER, et al.Biocompatibility of poly(D,L-lactic-co-hydroxymethyl glycolic acid) microspheres after subcutaneous and subcapsular renal injection. Int J Pharm, 2015; 482(1–2):99–109.
55.
HsuW, MaruyamaT. Analysis of skeletal stem cells by renal capsule transplantation and ex vivo culture systems. Front Physiol, 2023; 14:1143344.
56.
FanM, ZhangJ, XinH, et al.Current perspectives on role of MSC in renal pathophysiology. Front Physiol, 2018; 9:1323.
57.
PittengerMF, DischerDE, PéaultBM, et al.Mesenchymal stem cell perspective: Cell biology to clinical progress. NPJ Regen Med, 2019; 4:22.
58.
LiangX, DingY, ZhangY, et al.Paracrine mechanisms of mesenchymal stem cell-based therapy: Current status and perspectives. Cell Transplant, 2014; 23(9):1045–1059.
59.
KhubutiyaMS, VagabovAV, TemnovAA, et al.Paracrine mechanisms of proliferative, anti-apoptotic and anti-inflammatory effects of mesenchymal stromal cells in models of acute organ injury. Cytotherapy, 2014; 16(5):579–585.
60.
YamadaY, NakashimaA, DoiS, et al.Localization and maintenance of engrafted mesenchymal stem cells administered via renal artery in kidneys with ischemia-reperfusion injury. Int J Mol Sci, 2021;22(8).
61.
WangY, HeJ, PeiX, et al.Systematic review and meta-analysis of mesenchymal stem/stromal cells therapy for impaired renal function in small animal models. Nephrology (Carlton), 2013; 18(3):201–208.
62.
BurstVR, GillisM, PütschF, et al.Poor cell survival limits the beneficial impact of mesenchymal stem cell transplantation on acute kidney injury. Nephron Exp Nephrol, 2010; 114(3):e107–e116.
63.
HuangM, LiD, ChenJ, et al.Comparison of the treatment efficacy of umbilical mesenchymal stem cell transplantation via renal subcapsular and parenchymal routes in AKI-CKD mice. Stem Cell Res Ther, 2022; 13(1):128.
DamianoG, MaioneC, MaffongelliA, et al.Renal allograft compartment syndrome: Is it possible to prevent?. Transplant Proc, 2016; 48(2):340–343.
66.
MutoS, AsanoY. Electrical properties of the rabbit cortical collecting duct from obstructed kidneys after unilateral ureteral obstruction. Effects of renal decapsulation. J Clin Invest, 1994; 94(5):1846–1854.
67.
HumarA, SharpeJ, HollombyD. Salvage of a renal allograft with renal vein occlusion secondary to extrinsic compression. Am J Kidney Dis, 1996; 28(4):622–623.
68.
HebertLA, StuartKA, StemperJA. Effect of renal decapsulation on renal function. Am J Physiol, 1975; 229(3):632–639.
69.
HeroldJ, KaluckaJ. Angiogenesis in adipose tissue: The interplay between adipose and endothelial cells. Front Physiol, 2020; 11:624903.
70.
AmirianJ, VanTTT, BaeSH, et al.Examination of in vitro and in vivo biocompatibility of alginate-hyaluronic acid microbeads as a promising method in cell delivery for kidney regeneration. Int J Biol Macromol, 2017; 105(Pt 1):143–153.
71.
FengG, ZhangJ, LiY, et al.IGF-1 C domain-modified hydrogel enhances cell therapy for AKI. J Am Soc Nephrol, 2016; 27(8):2357–2369.
72.
GaoJ, LiuR, WuJ, et al.The use of chitosan based hydrogel for enhancing the therapeutic benefits of adipose-derived MSCs for acute kidney injury. Biomaterials, 2012; 33(14):3673–3681.
73.
ZulloJA, NadelEP, RabadiMM, et al.The secretome of hydrogel-coembedded endothelial progenitor cells and mesenchymal stem cells instructs macrophage polarization in endotoxemia. Stem Cells Transl Med, 2015; 4(7):852–861.
74.
TroyE, TilburyMA, PowerAM, et al.Nature-based biomaterials and their application in biomedicine. Polymers (Basel), 2021;13(19).
75.
HuangS, LiY, WangX, et al.Injectable co-gels of collagen and decellularized vascular matrix improve MSC-based therapy for acute kidney injury. J Biomater Sci Polym Ed, 2017; 28(18):2186–2195.
76.
ZhouC, ZhouL, LiuJ, et al.Kidney extracellular matrix hydrogel enhances therapeutic potential of adipose-derived mesenchymal stem cells for renal ischemia reperfusion injury. Acta Biomater, 2020; 115:250–263.
77.
Sobreiro-AlmeidaR, QuinteiraR, NevesNM. Renal regeneration: The role of extracellular matrix and current ECM-based tissue engineered strategies. Adv Healthc Mater, 2021; 10(14):e2100160.
78.
FuZ, ChuY, GengX, et al.Artificial kidney capsule packed with mesenchymal stem cell-laden hydrogel for the treatment of rhabdomyolysis-induced acute kidney injury. ACS Biomater Sci Eng, 2022; 8(4):1726–1734.
79.
LiuJ, ZhangL, YangZ, et al.Controlled release of paclitaxel from a self-assembling peptide hydrogel formed in situ and antitumor study in vitro. Int J Nanomedicine, 2011; 6:2143–2153.
80.
ChoSH, NohJR, ChoMY, et al.An injectable collagen/poly(γ-glutamic acid) hydrogel as a scaffold of stem cells and α-lipoic acid for enhanced protection against renal dysfunction. Biomater Sci, 2017; 5(2):285–294.
81.
BakotaEL, WangY, DaneshFR, et al.Injectable multidomain peptide nanofiber hydrogel as a delivery agent for stem cell secretome. Biomacromolecules, 2011; 12(5):1651–1657.
82.
ZhaoM, ZhouY, LiuS, et al.Control release of mitochondria-targeted antioxidant by injectable self-assembling peptide hydrogel ameliorated persistent mitochondrial dysfunction and inflammation after acute kidney injury. Drug Deliv, 2018; 25(1):546–554.
83.
NagaoRJ, XuJ, LuoP, et al.Decellularized human kidney cortex hydrogels enhance kidney microvascular endothelial cell maturation and quiescence. Tissue Eng Part A, 2016; 22(19–20):1140–1150.
84.
WangH, ShangY, ChenX, et al.Delivery of MSCs with a hybrid β-sheet peptide hydrogel consisting IGF-1C domain and D-form peptide for acute kidney injury therapy. Int J Nanomedicine, 2020; 15:4311–4324.
85.
ZhangR, HuZ, WangY, et al.A biomimetic double network hydrogel ameliorates renal fibrosis and promotes renal regeneration. J Mater Chem B, 2022; 10(45):9424–9437.
86.
LvY, ZhaoP, ChenG, et al.Effects of low-intensity pulsed ultrasound on cell viability, proliferation and neural differentiation of induced pluripotent stem cells-derived neural crest stem cells. Biotechnol Lett, 2013; 35(12):2201–2212.
87.
LingL, WeiT, HeL, et al.Low-intensity pulsed ultrasound activates ERK1/2 and PI3K-Akt signalling pathways and promotes the proliferation of human amnion-derived mesenchymal stem cells. Cell Prolif, 2017;50(6).
88.
LeeIC, LoTL, YoungTH, et al.Differentiation of neural stem/progenitor cells using low-intensity ultrasound. Ultrasound Med Biol, 2014; 40(9):2195–2206.
89.
LimK, KimJ, SeonwooH, et al.In vitro effects of low-intensity pulsed ultrasound stimulation on the osteogenic differentiation of human alveolar bone-derived mesenchymal stem cells for tooth tissue engineering. Biomed Res Int, 2013; 2013:269724.
90.
XuP, Gul-UludagH, AngWT, et al.Low-intensity pulsed ultrasound-mediated stimulation of hematopoietic stem/progenitor cell viability, proliferation and differentiation in vitro. Biotechnol Lett, 2012; 34(10):1965–1973.
91.
WangG, ZhangQ, ZhuoZ, et al.Effects of diagnostic ultrasound-targeted microbubble destruction on the homing ability of bone marrow stromal cells to the kidney parenchyma. Eur Radiol, 2016; 26(9):3006–3016.
92.
TangHL, WangZG, LiQ, et al.Targeted delivery of bone mesenchymal stem cells by ultrasound destruction of microbubbles promotes kidney recovery in acute kidney injury. Ultrasound Med Biol, 2012; 38(4):661–669.
93.
WangG, ZhangQ, ZhuoZ, et al.Enhanced homing of CXCR-4 modified bone marrow-derived mesenchymal stem cells to acute kidney injury tissues by micro-bubble-mediated ultrasound exposure. Ultrasound Med Biol, 2016; 42(2):539–548.
94.
HuangS, RenY, WangX, et al.Application of ultrasound-targeted microbubble destruction-mediated exogenous gene transfer in treating various renal diseases. Hum Gene Ther, 2019; 30(2):127–138.
95.
WuJ, LiRK. Ultrasound-targeted microbubble destruction in gene therapy: A new tool to cure human diseases. Genes Dis, 2017; 4(2):64–74.
96.
WuJ, XieF, LofJ, et al.Utilization of modified diagnostic ultrasound and microbubbles to reduce myocardial infarct size. Heart, 2015; 101(18):1468–1474.
97.
GaoS, ZhangY, WuJ, et al.Improvements in cerebral blood flow and recanalization rates with transcranial diagnostic ultrasound and intravenous microbubbles after acute cerebral emboli. Invest Radiol, 2014; 49(9):593–600.
98.
PorterTR, XieF, LofJ, et al.The thrombolytic effect of diagnostic ultrasound-induced microbubble cavitation in acute carotid thromboembolism. Invest Radiol, 2017; 52(8):477–481.
99.
FletcherSP, ChoiM, OgrodnikN, et al.A porcine model of transvertebral ultrasound and microbubble-mediated blood-spinal cord barrier opening. Theranostics, 2020; 10(17):7758–7774.
100.
FanCH, ChangEL, TingCY, et al.Folate-conjugated gene-carrying microbubbles with focused ultrasound for concurrent blood-brain barrier opening and local gene delivery. Biomaterials, 2016; 106:46–57.
101.
XiangX, TangY, LengQ, et al.Targeted gene delivery to the synovial pannus in antigen-induced arthritis by ultrasound-targeted microbubble destruction in vivo. Ultrasonics, 2016; 65:304–314.
102.
Di IanniT, BoseRJC, SukumarUK, et al.Ultrasound/microbubble-mediated targeted delivery of anticancer microRNA-loaded nanoparticles to deep tissues in pigs. J Control Release, 2019; 309:1–10.
103.
ZhangY, YeC, WangG, et al.Kidney-targeted transplantation of mesenchymal stem cells by ultrasound-targeted microbubble destruction promotes kidney repair in diabetic nephropathy rats. Biomed Res Int, 2013; 2013:526367.
104.
SunW, LiZ, ZhouX, et al.Efficient exosome delivery in refractory tissues assisted by ultrasound-targeted microbubble destruction. Drug Deliv, 2019; 26(1):45–50.
105.
WeiS, FuN, SunY, et al.Targeted contrast-enhanced ultrasound imaging of angiogenesis in an orthotopic mouse tumor model of renal carcinoma. Ultrasound Med Biol, 2014; 40(6):1250–1259.
106.
ChenHY, HuangXR, WangW, et al.The protective role of Smad7 in diabetic kidney disease: Mechanism and therapeutic potential. Diabetes, 2011; 60(2):590–601.
107.
KaSM, YehYC, HuangXR, et al.Kidney-targeting Smad7 gene transfer inhibits renal TGF-β/MAD homologue (SMAD) and nuclear factor κB (NF-κB) signalling pathways, and improves diabetic nephropathy in mice. Diabetologia, 2012; 55(2):509–519.
108.
DengQ, MiJ, DongJ, et al.Superiorly stable three-layer air microbubbles generated by versatile ethanol-water exchange for contrast-enhanced ultrasound theranostics. ACS Nano, 2023; 17(1):263–274.
109.
RoccaCJ, UrSN, HarrisonF, et al.rAAV9 combined with renal vein injection is optimal for kidney-targeted gene delivery: Conclusion of a comparative study. Gene Ther, 2014; 21(6):618–628.
110.
WoodardLE, ChengJ, WelchRC, et al.Kidney-specific transposon-mediated gene transfer in vivo. Sci Rep, 2017; 7:44904.
111.
WoodardLE, WelchRC, WilliamsFM, et al.Hydrodynamic renal pelvis injection for non-viral expression of proteins in the kidney. J Vis Exp, 2018(131).
112.
ChungDC, FogelgrenB, ParkKM, et al.Adeno-associated virus-mediated gene transfer to renal tubule cells via a retrograde ureteral approach. Nephron Extra, 2011; 1(1):217–223.
113.
AsicoLD, CuevasS, MaX, et al.Nephron segment-specific gene expression using AAV vectors. Biochem Biophys Res Commun, 2018; 497(1):19–24.
114.
OyamaN, KawaguchiM, ItakaK, et al.Efficient messenger RNA delivery to the kidney using renal pelvis injection in mice. Pharmaceutics, 2021;13(11).
115.
MaioneC, GambinoG, Di BonaA, et al.PTFE mesh in renal allograft compartment syndrome. Transplant Proc, 2006; 38(4):1049–1050.
116.
KashaniKB, MaoSA, SafadiS, et al.Association between kidney intracapsular pressure and ultrasound elastography. Crit Care, 2017; 21(1):251.
117.
ZhuG, WuD, WuK, et al.The retroperitoneal laparoscopic renal capsulectomy for spontaneous renal subcapsular fluid collection: A case-series report and literature review. Medicine (Baltimore), 2016; 95(21):e3751.
118.
ZhangX, ShiTP, LiHZ, et al.Laparo-endoscopic single site anatomical retroperitoneoscopic adrenalectomy using conventional instruments: Initial experience and short-term outcome. J Urol, 2011; 185(2):401–406.
119.
GrossiniE, MolinariC, PolleselloP, et al.Levosimendan protection against kidney ischemia/reperfusion injuries in anesthetized pigs. J Pharmacol Exp Ther, 2012; 342(2):376–388.
120.
Barrera-ChimalJ, Pérez-VillalvaR, OrtegaJA, et al.Intra-renal transfection of heat shock protein 90 alpha or beta (Hsp90α or Hsp90β) protects against ischemia/reperfusion injury. Nephrol Dial Transplant, 2014; 29(2):301–312.
121.
DoulamisIP, GuarientoA, DuignanT, et al.Mitochondrial transplantation by intra-arterial injection for acute kidney injury. Am J Physiol Renal Physiol, 2020; 319(3):F403–F413.
122.
JabbariH, RoushandehAM, RostamiMK, et al.Mitochondrial transplantation ameliorates ischemia/reperfusion-induced kidney injury in rat. Biochim Biophys Acta Mol Basis Dis, 2020; 1866(8):165809.
123.
ZhangL, ZhuXY, ZhaoY, et al.Selective intrarenal delivery of mesenchymal stem cell-derived extracellular vesicles attenuates myocardial injury in experimental metabolic renovascular disease. Basic Res Cardiol, 2020; 115(2):16.
124.
EirinA, ZhuXY, JonnadaS, et al.Mesenchymal stem cell-derived extracellular vesicles improve the renal microvasculature in metabolic renovascular disease in swine. Cell Transplant, 2018; 27(7):1080–1095.
125.
SuzukiH, OhtakeT, TsukiyamaT, et al.Acute kidney injury successfully treated with autologous granulocyte colony-stimulating factor-mobilized peripheral blood CD34-positive cell transplantation: A first-in-human report. Stem Cells Transl Med, 2021; 10(9):1253–1257.
126.
LeeKW, KimTM, KimKS, et al.Renal ischemia-reperfusion injury in a diabetic monkey model and therapeutic testing of human bone marrow-derived mesenchymal stem cells. J Diabetes Res, 2018; 2018:5182606.
127.
EirinA, ZhuXY, FergusonCM, et al.Intra-renal delivery of mesenchymal stem cells attenuates myocardial injury after reversal of hypertension in porcine renovascular disease. Stem Cell Res Ther, 2015; 6(1):7.
128.
MoghadasaliR, AzarniaM, HajinasrollahM, et al.Intra-renal arterial injection of autologous bone marrow mesenchymal stromal cells ameliorates cisplatin-induced acute kidney injury in a rhesus Macaque mulatta monkey model. Cytotherapy, 2014; 16(6):734–749.
129.
NieW, LiM, LiuB, et al.A circular RNA, circPTPN14, increases MYC transcription by interacting with FUBP1 and exacerbates renal fibrosis. Cell Mol Life Sci, 2022; 79(12):595.
130.
XuD, ChenPP, ZhengPQ, et al.KLF4 initiates sustained YAP activation to promote renal fibrosis in mice after ischemia-reperfusion kidney injury. Acta Pharmacol Sin, 2021; 42(3):436–450.
131.
KimJH, YangH, KimMW, et al.The delivery of the recombinant protein cocktail identified by stem cell-derived secretome analysis accelerates kidney repair after renal ischemia-reperfusion injury. Front Bioeng Biotechnol, 2022; 10:848679.
132.
PaglioneD, GattaL, CavallariG, et al.Acute kidney ischemic injury in a rat model treated by human omental mesenchymal stem cells. Transplant Proc, 2020; 52(10):2977–2979.
133.
HavakhahS, SankianM, KazemzadehGH, et al.In vivo effects of allogeneic mesenchymal stem cells in a rat model of acute ischemic kidney injury. Iran J Basic Med Sci, 2018; 21(8):824–831.
134.
ZhangW, LiuL, HuoY, et al.Hypoxia-pretreated human MSCs attenuate acute kidney injury through enhanced angiogenic and antioxidative capacities. Biomed Res Int, 2014; 2014:462472.
135.
La MannaG, BianchiF, CappuccilliM, et al.Mesenchymal stem cells in renal function recovery after acute kidney injury: Use of a differentiating agent in a rat model. Cell Transplant, 2011; 20(8):1193–1208.
136.
ChenS, HuangH, LiuY, et al.Renal subcapsular delivery of PGE(2) promotes kidney repair by activating endogenous Sox9(+) stem cells. iScience, 2021; 24(11):103243.
137.
SorannoDE, RodellCB, AltmannC, et al.Delivery of interleukin-10 via injectable hydrogels improves renal outcomes and reduces systemic inflammation following ischemic acute kidney injury in mice. Am J Physiol Renal Physiol, 2016; 311(2):F362–F372.
138.
TsurkanMV, HauserPV, ZierisA, et al.Growth factor delivery from hydrogel particle aggregates to promote tubular regeneration after acute kidney injury. J Control Release, 2013; 167(3):248–255.
139.
ZhouY, XuH, XuW, et al.Exosomes released by human umbilical cord mesenchymal stem cells protect against cisplatin-induced renal oxidative stress and apoptosis in vivo and in vitro. Stem Cell Res Ther, 2013; 4(2):34.
140.
OkaM, KameishiS, ChoYK, et al.Clinically relevant mesenchymal stem/stromal cell sheet transplantation method for kidney disease. Tissue Eng Part C Methods, 2023; 29(2):54–62.
141.
MiyabeY, SekiyaS, SugiuraN, et al.Renal subcapsular transplantation of hepatocyte growth factor-producing mesothelial cell sheets improves ischemia-reperfusion injury. Am J Physiol Renal Physiol, 2019; 317(2):F229–F239.
142.
ChengK, RaiP, PlagovA, et al.Transplantation of bone marrow-derived MSCs improves cisplatinum-induced renal injury through paracrine mechanisms. Exp Mol Pathol, 2013; 94(3):466–473.
